Clinical Trials Logo

Plague clinical trials

View clinical trials related to Plague.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05506969 Active, not recruiting - Clinical trials for Vaccine-Preventable Diseases

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Start date: August 9, 2022
Phase: Phase 2
Study type: Interventional

Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age

NCT ID: NCT05330624 Active, not recruiting - Plague Clinical Trials

Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

Start date: May 8, 2020
Phase: Phase 2
Study type: Interventional

Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality. It has a long history for plague as an agent of biowarfare, and pose a serious threat to international security. Althought the killed whole-cell plague vaccine and live attenuated vaccine has been licensed. They are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. In the last twenty years, it have focused on recombinant subunit vaccines which were formed F1 and V antigens as the main composition provide greater protection than vaccines comprised of either subunit alone. This study was aim to exploring the safety and immunogenicity of a new type plague subunit vaccine which comprised natural F1 antigen and recombined V antigen (F1+rV) in two immunization regimens.